期刊
LEUKEMIA & LYMPHOMA
卷 62, 期 14, 页码 3384-3393出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2021.1966782
关键词
COVID-19; Haemato-oncological; retrospective; multicenter
This study found that COVID-19 infection is particularly severe in patients with hematological malignancies. Factors like age over 70, hypertension, and active hematological cancer treatment may increase the risk of severe disease or hospitalization, while remdesivir stands out as the most effective treatment among those examined.
This national Israeli multicenter retrospective study aimed to characterize the clinical course of COVID-19 infection among patients with hematological malignancies, with special emphasis on treatment efficacy and outcome. Clinical and laboratory data from haemato-oncological patients diagnosed with COVID-19 from 16 medical centers were centrally reported. Multivariate regression analyses were used to determine variables associated with severe disease, hospitalization, and mortality. In total, 313 patients were included: 103 (35.7%) developed severe/critical respiratory infection, 178 (61.4%) were hospitalized, and 60 (20.0%) died. Age > 70 years was associated with severe/critical disease (p = 0.036) and mortality (p = 0.023), hypertension with severe/critical disease (p = 0.046) and hospitalization (p = 0.001), active haemato-oncological treatment with hospitalization (p = 0.009), and remdesivir treatment was associated with decreased mortality (p = 0.021). Convalescent plasma, enoxaparin, and corticosteroids resulted in no clinical benefit. In conclusion, COVID-19 infection seems particularly severe in patients with hematological malignancies, and of all examined therapies, remdesivir appears to be the most effective.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据